Nine-year experience in the treatment of patients with diffuse large B-cell lymphosarcoma

Abstract

Aim. To ascertain indications to standard (CHOP-21/R-CHOP-21) and intensive (mNHL-BFM-90) treatment in patients with diffuse large B-cell lymphosarcoma (DLBCL) with involvement of lymphoid organs.
Material and methods. The trial, performed from January 2002 to December 2010, enrolled 139 DLBCL patients with affected lymph nodes (LN), tonsils, spleen, bone marrow (BM). The diagnosis was made according to WHO criteria. The patients were examined according to the protocol of lymphoproliferative diseases. Biopsy material from all 139 patients was studied immunohistochemically on paraffin blocks (LN, tonsils, spleen, BM) using a wide panel of antibodies. The same examinations of BM were made in all 18 cases of BM involvement. Cytogenetic examination was performed in 106 patients: 48 standard cytogenetic tests, 139 - FISH for t (14;18) as well as rearrangement of locus 3q27. Patients with a poor prognosis (n = 86, 61.8%) received intensive therapy according to mNHL-BFM-90 program. The signs of a poor prognosis were the following: massive tumor (tumor size more than 7.5 cm), invasion into the adjacent organs or tissues, stage III-IV disease by Enn-Erbor, high concentration of LDG. Patients without a poor prognosis (n = 53, 38.2%) received standard treatment CHOP-21 (n = 28) or R-CHOP-21 (n = 25).
Results. A complete remission without recurrences was achieved in all 53 patients without signs of unfavourable prognosis (100%). Overall 5-year survival was 96%, 2 patients died in remission of other causes. Of 86 patients with a poor prognosis a complete remission was achieved in 64 (74.4%) patients. Overall and recurrence-free 5-year survival was 65 and 86%, respectively.
Conclusion. Standard treatment provided long-term complete remission in all the patients without poor prognosis. Intensive (mNHL-BFM-90) treatment produced the best results in generalized lesion without BM involvement. Overall 5-year survival was 84% in these patients and 12% in patients with BM involvement.

About the authors

Aminat Umaraskhabovna Magomedova

Email: maminat@mail. ru

S K Kravchenko

A M Kremenetskaya

E A Zvonkov

E A Baryakh

Ya K Mangasarova

I B Kaplanskaya

R S Samoylova

I A Vorob'ev

T N Obukhova

S R Karagyulyan

E M Shulutko

G M Galstyan

D S Mar'in

N G Gabeeva

A I Vorob'ev

A U Magomedova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

S K Kravchenko

Hematological Research Center, Moscow

Hematological Research Center, Moscow

A M Kremenetskaya

Hematological Research Center, Moscow

Hematological Research Center, Moscow

E A Zvonkov

Hematological Research Center, Moscow

Hematological Research Center, Moscow

E A Baryakh

Hematological Research Center, Moscow

Hematological Research Center, Moscow

Ya K Mangasarova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

I B Kaplanskaya

Hematological Research Center, Moscow

Hematological Research Center, Moscow

R S Samoilova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

I A Vorobiev

Hematological Research Center, Moscow

Hematological Research Center, Moscow

T N Obukhova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

S R Karagyulyan

Hematological Research Center, Moscow

Hematological Research Center, Moscow

E M Shulutko

Hematological Research Center, Moscow

Hematological Research Center, Moscow

G M Galstyan

Hematological Research Center, Moscow

Hematological Research Center, Moscow

D S Maryin

Hematological Research Center, Moscow

Hematological Research Center, Moscow

N G Gabeeva

Hematological Research Center, Moscow

Hematological Research Center, Moscow

A I Vorobiev

Hematological Research Center, Moscow

Hematological Research Center, Moscow

References

  1. Harris N. L., Jaffe E. S., Diebold J. et al. World Health Organization classification diseases of the hematopoetic and lymphoid tissues: report of the clinical advisory committee meeting. - Airline House, Virginia, November 1997. J. Clin. Oncol. 1999; 17 (12): 3835-3849.
  2. Воробьев А. И. Руководство по гематологии. М. : Ньюдиамед; 2003; т. 2: 55, 98-100.
  3. Shipp M. A., Ross K. N., Tramayo P. et al. Diffuse large B-cell lymphoma outcome prediction by gene expression profiling and supervised machine learning. Nature 2002; 8 (1): 68-74.
  4. Barrans S., Carter I., Morgan G. J. et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99 (4): 1136-1142.
  5. Barrans S., Evans P., Connor S. et аl. The t(14; 18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin. Cancer Res. 2003; 9. 2133-2139.
  6. Winter J. N., Weller E. A., Horning S. J. et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: prospective correlative study. Blood 2006; 107 (11): 4207-4213.
  7. Leval L., Harris N. L. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology 2003; 43: 509-528.
  8. Rosenwald A., Hoeller S., Ott G. Clinical impact of gene expression profiling in aggressive lymphoma. Hematology 2006; 2: 146-150.
  9. Hasselblom S., Riddell В., Nilsson-Ehle H. et al. The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma - a population - based study. Leukemia and Lymphoma 2007; 48 (4): 736-745.
  10. Rosenwald A., Wright G., Chan W. C. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N. Engl. J. Med. 2002; 346: 1937-1947.
  11. Shipp V. F., Harrington D. P. A predictive model for agressive non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 329 (14): 987-994.
  12. Reiter A., Schrappe M., Ludwig W. D. et al. Improved treatment results in childhood B-cell neoplasm's with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM-90. Blood 1999; 94 (10): 3294-3306.
  13. Магомедова А. У., Кравченко С. К., Кременецкая A. M. и др. Модифицированная программа NHL-BFM-90 в лечении больных диффузной В-крупноклеточной лимфосаркомой. Тер. арх. 2006; 10: 44-47.
  14. Cheson B. D., Horning S. J., Coiffier B. et al. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. J. Clin. Oncol. 1999; 17: 1244- 1253.
  15. Магомедова А. У., Кравченко С. К., Кременецкая A. M. и др. Эффективность курса CHOP-21 в терапии диффузной В-крупноклеточной лимфосаркомы. Тер. apx. 2005; 7: 58- 61.
  16. Воробьев А. И. Руководство по гематологии. М. : Ньюдиамед; 2003; т. 1: 46-50.
  17. Воробьев А. И., Бриллиант М. Д. Лимфоцитома селезенки и классификация лимфоцитом. Тер. арх. 1982; 8: 8-14.

Copyright (c) 2011 Magomedova A.U., Kravchenko S.K., Kremenetskaya A.M., Zvonkov E.A., Baryakh E.A., Mangasarova Y.K., Kaplanskaya I.B., Samoylova R.S., Vorob'ev I.A., Obukhova T.N., Karagyulyan S.R., Shulutko E.M., Galstyan G.M., Mar'in D.S., Gabeeva N.G., Vorob'ev A.I., Magomedova A.U., Kravchenko S.K., Kremenetskaya A.M., Zvonkov E.A., Baryakh E.A., Mangasarova Y.K., Kaplanskaya I.B., Samoilova R.S., Vorobiev I.A., Obukhova T.N., Karagyulyan S.R., Shulutko E.M., Galstyan G.M., Maryin D.S., Gabeeva N.G., Vorobiev A.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies